Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age

Journal of Clinical Oncology

Volumn 29, Issue 33, 2011, Pages 4358-4364

  Taggart, Denah R ^a   London, Wendy B ^b   Schmidt, Mary Lou ^c   DuBois, Steven G ^a   Monclair, Tom F ^e   Nakagawara, Akira ^f   De Bernardi, Bruno ^g   Ambros, Peter F ^h   Pearson, Andrew D J ⁱ   Cohn, Susan L ^d   Matthay, Katherine K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f CHIBA CANCER CENTER   (Japan)

^g G GASLINI INSTITUTE   (Italy)

^h ST ANNA CHILDREN S HOSPITAL   (Austria)

ⁱ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LACTATE DEHYDROGENASE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILD; CHROMOSOME 11Q; CHROMOSOME 1P; CHROMOSOME ABERRATION; EVENT FREE SURVIVAL; GENE; HIGH RISK PATIENT; HUMAN; INFANT; INTENSIVE CARE; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; METASTASIS; METASTATIC NEUROBLASTOMA; MITOSIS KARYORRHEXIS INDEX; MYCN GENE; NEUROBLASTOMA; NEWBORN; OVERALL SURVIVAL; PLOIDY; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; RISK ASSESSMENT;

AGE FACTORS; BRAIN NEOPLASMS; HUMANS; INFANT; INFANT, NEWBORN; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM STAGING; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROGNOSIS;

EID: 81755184446     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.9570     Document Type: Article

References (33)

1. D'Angio G, Evans A, Koop C: Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1:1046-1049, 1971
2. Brodeur GM, Pritchard J, Berthold F, et al.: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993 (Pubitemid 23228250)
3. Schleiermacher G, Rubie H, Hartmann O, et al.: Treatment of stage 4s neuroblastoma: Report of 10 years' experience of the French Society of Paediatric Oncology (SFOP). Br J Cancer 89:470-476, 2003 (Pubitemid 37026427)
4. Nickerson HJ, Matthay KK, Seeger RC, et al.: Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: A Children's Cancer Group study. J Clin Oncol 18:477-486, 2000 (Pubitemid 30078529)
5. Bourhis J, Dominici C, McDowell H, et al.: N-myc genomic content and DNA ploidy in stage IVS neuroblastoma. J Clin Oncol 9:1371-1375, 1991
6. DuBois SG, Kalika Y, Lukens JN, et al.: Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 21:181-189, 1999 (Pubitemid 30306028)
7. Hachitanda Y, Hata J: Stage IVS neuroblastoma: A clinical, histological, and biological analysis of 45 cases. Hum Pathol 27:1135-1138, 1996 (Pubitemid 26374930)
8. Wang Q, Diskin S, Rappaport E, et al.: Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 66:6050-6062, 2006
9. Katzenstein HM, Bowman LC, Brodeur GM, et al.: Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D S neuroblastoma: The pediatric oncology group experience - A pediatric oncology group study. J Clin Oncol 16:2007-2017, 1998 (Pubitemid 28265034)
10. Guo C, White PS, Weiss MJ, et al.: Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 18:4948-4957, 1999 (Pubitemid 29425301)
11. Maris JM, Hogarty MD, Bagatell R, et al.: Neuroblastoma. Lancet 369:2106-2120, 2007 (Pubitemid 46935947)
12. Maris JM, Matthay KK: Molecular biology of neuroblastoma. J Clin Oncol 17:2264-2279, 1999 (Pubitemid 29318861)
13. van Noesel MM, Heahlen K, Hakvoort- Cammel FG, et al.: Neuroblastoma 4S: A heterogeneous disease with variable risk factors and treatment strategies. Cancer 80:834-843, 1997
14. Schneiderman J, London WB, Brodeur GM, et al.: Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: A report from the Children's Oncology Group. J Clin Oncol 26:913-918, 2008 (Pubitemid 351398084)
15. George RE, London WB, Cohn SL, et al.: Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 23:6466-6473, 2005 (Pubitemid 46190237)
16. Schmidt ML, Lal A, Seeger RC, et al.: Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: A Children's Cancer Group Study. J Clin Oncol 23: 6474-6480, 2005 (Pubitemid 46190238)
17. Monclair T, Brodeur GM, Ambros PF, et al.: The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report. J Clin Oncol 27:298-303, 2009
18. Shimada H, Ambros IM, Dehner LP, et al.: The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86:364-372, 1999 (Pubitemid 29327594)
19. Bagatell R, Beck-Popovic M, London WB, et al.: Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: A report from the International Neuroblastoma Risk Group database. J Clin Oncol 27: 365-370, 2009
20. Ambros PF, Ambros IM, Brodeur GM, et al.: International consensus for neuroblastoma molecular diagnostics: Report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 100:1471-1482, 2009
21. Cohn SL, Pearson AD, London WB, et al.: The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J Clin Oncol 27:289-297, 2009
22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
23. Peto R, Pike MC, Armitage P, et al.: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: I. Introduction and design. Br J Cancer 34:585-612, 1976 (Pubitemid 8004970)
24. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
25. Segal MR: Extending the elements of tree-structured regression. Stat Methods Med Res 4: 219-236, 1995
26. Segal MR, Bloch DA: A comparison of estimated proportional hazards models and regression trees. Stat Med 8:539-550, 1989 (Pubitemid 19116000)
27. London WB, Castleberry RP, Matthay KK, et al.: Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 23:6459-6465, 2005 (Pubitemid 46190236)
28. Schmidt ML, Lukens JN, Seeger RC, et al.: Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol 18:1260-1268, 2000 (Pubitemid 30159844)
29. De Bernardi B, Gerrard M, Boni L, et al.: Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol 27:1034-1040, 2009
30. Canete A, Gerrard M, Rubie H, et al.: Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: The International Society of Paediatric Oncology European neuroblastoma experience. J Clin Oncol 27: 1014-1019, 2009
31. Baker DL, Schmidt ML, Cohn SL, et al.: Outcome after reduced chemotherapy for intermediaterisk neuroblastoma. N Engl J Med 363:1313-1323, 2010
32. Attiyeh EF, London WB, Mosse YP, et al.: Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353:2243-2253, 2005 (Pubitemid 41697287)
33. Spitz R, Hero B, Simon T, et al.: Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res 12:3368-3373, 2006